<![CDATA[Five-Year KEYNOTE-775 Data Confirm Durable Benefit With Lenvatinib Combo]]>

Data ReadoutpositiveLenvatinibPembrolizumabPositive

AI Analysis

Summary

Five-year follow-up data from KEYNOTE-775 demonstrated durable benefit with lenvatinib plus pembrolizumab combination therapy in dMMR endometrial cancer, achieving a 37% overall survival rate. This long-term efficacy data supports the sustained clinical value of the combination regimen.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Five-year follow-up data from KEYNOTE-775 showed 37% overall survival rate with lenvatinib plus pembrolizumab combination in dMMR endometrial cancer

Importance:6/10

Sentiment:

0.70

oncologyendometrial cancerdMMRKEYNOTE-775long-term datacombination therapy

Related Companies

$MRK

Read the original article

Published by Cancer Network on August 22, 2026 2:00 PM

Read Original